NO20065489L - Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer - Google Patents

Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer

Info

Publication number
NO20065489L
NO20065489L NO20065489A NO20065489A NO20065489L NO 20065489 L NO20065489 L NO 20065489L NO 20065489 A NO20065489 A NO 20065489A NO 20065489 A NO20065489 A NO 20065489A NO 20065489 L NO20065489 L NO 20065489L
Authority
NO
Norway
Prior art keywords
tieno
carbonitriles
pyridine
protein kinase
kinase inhibitors
Prior art date
Application number
NO20065489A
Other languages
English (en)
Norwegian (no)
Inventor
Diane Harris Boschelli
Nan Zhang
Haris Durutlic
Biqi Wu
Ana Carolina Barrios Sosa
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065489(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065489L publication Critical patent/NO20065489L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
NO20065489A 2004-05-14 2006-11-28 Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer NO20065489L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/845,710 US7276519B2 (en) 2002-11-25 2004-05-14 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
PCT/US2005/016150 WO2005113560A2 (en) 2004-05-14 2005-05-10 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
NO20065489L true NO20065489L (no) 2006-11-28

Family

ID=35149207

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065489A NO20065489L (no) 2004-05-14 2006-11-28 Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer

Country Status (20)

Country Link
US (2) US7276519B2 (ja)
EP (1) EP1756117A2 (ja)
JP (1) JP2007537262A (ja)
KR (1) KR20070015575A (ja)
CN (1) CN1950379A (ja)
AR (1) AR050248A1 (ja)
AU (1) AU2005245820A1 (ja)
BR (1) BRPI0511089A (ja)
CA (1) CA2564530A1 (ja)
CR (1) CR8787A (ja)
EC (1) ECSP067087A (ja)
GT (1) GT200500109A (ja)
MX (1) MXPA06012900A (ja)
NO (1) NO20065489L (ja)
PA (1) PA8633201A1 (ja)
PE (1) PE20060355A1 (ja)
RU (1) RU2006137476A (ja)
TW (1) TW200602348A (ja)
WO (1) WO2005113560A2 (ja)
ZA (1) ZA200609422B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589877A1 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
CA2589779A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
TW200900408A (en) * 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
ES2435918T3 (es) * 2008-09-26 2013-12-26 National Health Research Institutes Compuestos multicíclicos condensados como inhibidores de las proteína-cinasas
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
WO2013117285A1 (en) * 2012-02-09 2013-08-15 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
BR9914164A (pt) * 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DK1171440T3 (da) 1999-04-21 2004-08-02 Wyeth Corp Substituerede 3-cyano-[1,7]-, [1,5]- og [1,8]-naphthyridininhibitorer af tyrosinkinaser
ES2281372T3 (es) 1999-12-29 2007-10-01 Wyeth Inhibidores de proteina-quinasa triciclicos.
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001094353A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1337513A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa

Also Published As

Publication number Publication date
CN1950379A (zh) 2007-04-18
US20040242883A1 (en) 2004-12-02
ZA200609422B (en) 2008-07-30
WO2005113560A3 (en) 2006-01-12
CR8787A (es) 2007-10-02
RU2006137476A (ru) 2008-06-20
EP1756117A2 (en) 2007-02-28
TW200602348A (en) 2006-01-16
WO2005113560A2 (en) 2005-12-01
BRPI0511089A (pt) 2007-12-26
AU2005245820A1 (en) 2005-12-01
US7276519B2 (en) 2007-10-02
PE20060355A1 (es) 2006-05-11
US20080070913A1 (en) 2008-03-20
PA8633201A1 (es) 2006-05-16
GT200500109A (es) 2005-12-23
MXPA06012900A (es) 2007-01-26
CA2564530A1 (en) 2005-12-01
ECSP067087A (es) 2007-01-26
AR050248A1 (es) 2006-10-11
JP2007537262A (ja) 2007-12-20
KR20070015575A (ko) 2007-02-05

Similar Documents

Publication Publication Date Title
NO20065489L (no) Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer
NO20051928L (no) Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.
HK1067120A1 (en) Glutaminyl based dpiv inhibitors
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
WO2006050109A3 (en) Novel kinase inhibitors
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
SG156650A1 (en) Thienopyrimidines useful as aurora kinase inhibitors
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20030896L (no) Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
TW200716617A (en) Pyrazole compounds useful as protein kinase inhibitors
WO2002076976A3 (en) Rho-kinase inhibitors
WO2002076977A3 (en) Rho-kinase inhibitors
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
EA200700918A1 (ru) Ингибиторы c - fms киназы
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
WO2006004924A3 (en) Imidazolo-related compounds, compositions and methods for their use
MY129491A (en) Hydrazono-malonitriles
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
EA200702027A1 (ru) Дерматологические композиции и соли для лечения дерматологических заболеваний
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
PE20060495A1 (es) 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7-{[5-(amino-sustituido) metil]-3-furil}-3-quinolincarbonitrilos como inhibidores de quinasa
WO2005007092A3 (en) Novel chemical compounds